Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation - An update of existing recommendations

被引：2

作者：

Arns, W. ^{[1
]}

Budde, K. ^{[2
]}

Eitner, F. ^{[3
]}

Gwinner, W. ^{[4
]}

Hugo, C. ^{[5
]}

Pressmar, K. ^{[6
]}

Weimann, A. ^{[7
]}

Witzke, O. ^{[8
]}

机构：

[1] Univ Witten Herdecke, Klinikum Koln Merheim, Med Klin Nephrol 1, Witten, Germany

[2] Charite Campus Mitte, Klin Nephrol, Berlin, Germany

[3] Klinikum RWTH Aachen, Med Klin 2, Aachen, Germany

[4] Hannover Med Sch, Klin Nieren & Hochdruckkrankheiten, D-30623 Hannover, Germany

[5] Nephrol Univ Klinikum Dresden, Med Klin & Poliklin 3, Dresden, Germany

[6] Univ Klinikum Erlangen, Med Klin Nephrol & Hypertensiol 4, Erlangen, Germany

[7] Univ Klinikum Leipzig, Chirurg Klin & Poliklin Transplantat Ambulanz 2, Leipzig, Germany

[8] Univ Duisburg Essen, Klin Nephrol, Univ Klinikum Essen, Duisburg, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2011年 / 136卷 / 49期

关键词：

calcineurin inhibitor toxicity; mTOR inhibitor; sirolimus; chronic allograft nephropathy; EARLY CYCLOSPORINE WITHDRAWAL; ALLOGRAFT RECIPIENTS; KIDNEY-TRANSPLANTATION; MYCOPHENOLATE-MOFETIL; RAPAMYCIN INHIBITORS; MAINTENANCE THERAPY; PHASE-III; IMMUNOSUPPRESSION; EFFICACY; COMPLICATIONS;

D O I：

10.1055/s-0031-1292822

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2554 / 2559

页数：6